Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diamond Shruumz is a brand of edible products—including chocolate bars, gummies, and cones—marketed as "microdose" or psychedelic mushroom-infused edibles. These products have been found to contain a combination of psychoactive and pharmacologically active substances, including 4-acetoxy-N,N-dimethyltryptamine (4-acetoxy-DMT, also known as O-acetylpsilocin or psilacetin), psilocin (a Schedule I-controlled substance), muscimol (a compound from Amanita mushrooms), ibotenic acid, pregabalin (a prescription drug), and kavalactones such as desmethoxyyangonin, dihydrokavain, and kavain. The mechanism of action involves serotonergic hallucinogenic activity via 4-acetoxy-DMT/psilocin at serotonin receptors; GABAergic effects from muscimol; gabapentinoid activity from pregabalin; and additional CNS effects from kavalactones. The products have been linked to severe adverse health events including seizures, loss of consciousness, respiratory failure, abnormal heart rates/blood pressure, hallucinations, agitation/confusion, nausea/vomiting/abdominal pain. As a result of these findings and associated illnesses—including hospitalizations and deaths—the FDA has issued recalls for all Diamond Shruumz products[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Diamond Shruumz.